File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques

TitlePegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques
Authors
Issue Date2004
Citation
Nature Medicine, 2004, v. 10, n. 3, p. 290-293 How to Cite?
AbstractThe primary cause of severe acute respiratory syndrome (SARS) is a newly discovered coronavirus. Replication of this SARS coronavirus (SCV) occurs mainly in the lower respiratory tract, and causes diffuse alveolar damage. Lack of understanding of the pathogenesis of SARS has prevented the rational development of a therapy against this disease. Here we show extensive SCV antigen expression in type 1 pneumocytes of experimentally infected cynomolgus macaques (Macaca fascicularis) at 4 d postinfection (d.p.i.), indicating that this cell type is the primary target for SCV infection early in the disease, and explaining the subsequent pulmonary damage. We also show that prophylactic treatment of SCV-infected macaques with the antiviral agent pegylated interferon-α (IFN-α) significantly reduces viral replication and excretion, viral antigen expression by type 1 pneumocytes and pulmonary damage, compared with untreated macaques. Postexposure treatment with pegylated IFN-α yielded intermediate results. We therefore suggest that pegylated IFN-α protects type 1 pneumocytes from SCV infection, and should be considered a candidate drug for SARS therapy.
Persistent Identifierhttp://hdl.handle.net/10722/199906
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHaagmans, Bart L.-
dc.contributor.authorKuiken, Thijs-
dc.contributor.authorMartina, Byron Ee E-
dc.contributor.authorFouchier, Ron AM M-
dc.contributor.authorRimmelzwaan, Guus F.-
dc.contributor.authorVan Amerongen, Geert-
dc.contributor.authorVan Riel, Debby A J-
dc.contributor.authorDe Jong, Ton-
dc.contributor.authorItamura, Shigeyuki-
dc.contributor.authorChan, Kwokhung-
dc.contributor.authorTashiro, Masato-
dc.contributor.authorOsterhaus, Albert DME M E-
dc.date.accessioned2014-07-26T23:10:53Z-
dc.date.available2014-07-26T23:10:53Z-
dc.date.issued2004-
dc.identifier.citationNature Medicine, 2004, v. 10, n. 3, p. 290-293-
dc.identifier.urihttp://hdl.handle.net/10722/199906-
dc.description.abstractThe primary cause of severe acute respiratory syndrome (SARS) is a newly discovered coronavirus. Replication of this SARS coronavirus (SCV) occurs mainly in the lower respiratory tract, and causes diffuse alveolar damage. Lack of understanding of the pathogenesis of SARS has prevented the rational development of a therapy against this disease. Here we show extensive SCV antigen expression in type 1 pneumocytes of experimentally infected cynomolgus macaques (Macaca fascicularis) at 4 d postinfection (d.p.i.), indicating that this cell type is the primary target for SCV infection early in the disease, and explaining the subsequent pulmonary damage. We also show that prophylactic treatment of SCV-infected macaques with the antiviral agent pegylated interferon-α (IFN-α) significantly reduces viral replication and excretion, viral antigen expression by type 1 pneumocytes and pulmonary damage, compared with untreated macaques. Postexposure treatment with pegylated IFN-α yielded intermediate results. We therefore suggest that pegylated IFN-α protects type 1 pneumocytes from SCV infection, and should be considered a candidate drug for SARS therapy.-
dc.languageeng-
dc.relation.ispartofNature Medicine-
dc.titlePegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1038/nm1001-
dc.identifier.pmid14981511-
dc.identifier.scopuseid_2-s2.0-2342645538-
dc.identifier.volume10-
dc.identifier.issue3-
dc.identifier.spage290-
dc.identifier.epage293-
dc.identifier.isiWOS:000189297700041-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats